The demo reached equally its Major endpoints, with semaglutide 2.4 mg demonstrating statistically significant and exceptional advancements in liver fibrosis without having worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH when compared with placebo.oneAssuming the above mentioned